Published in:
01-04-2013 | Editorial
Use of regadenoson in end-stage renal disease
Authors:
Ami E. Iskandrian, MD, MACC, Fadi G. Hage, MD, FACC, Jaekyeong Heo, MD, FACC
Published in:
Journal of Nuclear Cardiology
|
Issue 2/2013
Login to get access
Excerpt
Regadenoson has rapidly become the pharmacological stress agent of choice in the United States since its approval by the Food and Drug Administration in April 2008.
1-
5 The effect of regadenoson on myocardial blood flow is rapid necessitating the injection of radionuclide tracer 30 seconds after its injection as a bolus. The terminal part of the triphasic half-life is not associated with significant drug effect of any sort, which is important as prolonged monitoring of the patient is unnecessary. Almost 57% of the drug is excreted unchanged in the urine, which begs the question of safety in patients with impaired renal function.
6,
7 …
